Immunogenicity and effectiveness of an mRNA therapeutic vaccine for HPV-related malignancies
Life Science Alliance · 2024-06 · 7 (6) · e202302448
DOI: 10.26508/lsa.202302448 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life Science Alliance, online erschienen am 21.03.2024. Verfasst von Jing Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medicinal Biotechnology, Chinese Academy of Medical Science, Beijing, China. Hauptthemen laut MEDLINE: Papillomavirus Infections, Neoplasms, Papillomavirus Vaccines. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CAMS | Chinese Academy of Medical Sciences Initiative for Innovative Medicine, MOST | National Natural Science Foundation of China, National Center of Technology Innovation for Biopharmaceuticals.
Abstract (Originalsprache)
Human papillomavirus (HPV) infections account for several human cancers. There is an urgent need to develop therapeutic vaccines for targeting preexisting high-risk HPV (such as HPV 16 and 18) infections and lesions, which are insensitive to preventative vaccines. In this study, we developed a lipid nanoparticle–formulated mRNA-based HPV therapeutic vaccine (mHTV), mHTV-02, targeting the E6/E7 of HPV16 and HPV-18. mHTV-02 dramatically induced antigen-specific cellular immune response and robust memory T-cell immunity in mice, besides significant CD8 + T-cell infiltration and cytotoxicity in TC-1 tumors expressing HPV E6/E7, resulting in tumor regression and prolonged survival in mice. Moreover, evaluation of routes of administration found that intramuscular or intratumoral injection of mHTV-02 displayed significant therapeutic effects. In contrast, intravenous delivery of the vaccine barely showed any benefit in reducing tumor size or improving animal survival. These data together support mHTV-02 as a candidate therapeutic mRNA vaccine via specific administration routes for treating malignancies caused by HPV16 or HPV18 infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Medicinal Biotechnology, Chinese Academy of Medical Science, Beijing, China.
- RinuaGene Biotechnology Co., Ltd., Suzhou, China.
- RinuaGene Biotechnology Co., Ltd., Suzhou, China weiguo.zhang@rinuagene.com.
- RinuaGene Biotechnology Co., Ltd., Suzhou, China yijie.dong@rinuagene.com.
- Institute of Medicinal Biotechnology, Chinese Academy of Medical Science, Beijing, China shancen@imb.pumc.edu.cn.
Förderung
- CAMS | Chinese Academy of Medical Sciences Initiative for Innovative Medicine
- MOST | National Natural Science Foundation of China
- National Center of Technology Innovation for Biopharmaceuticals
Zitieren
APA
Wang, J., Ma, L., Chen, Y., Zhou, R., Wang, Q., Zhang, T., Yi, D., Liu, Q., Zhang, Y., Zhang, W., Dong, Y., & Cen, S. (2024). Immunogenicity and effectiveness of an mRNA therapeutic vaccine for HPV-related malignancies. Life Science Alliance, 7(6), e202302448. https://doi.org/10.26508/lsa.202302448
Vancouver
Wang J, Ma L, Chen Y, Zhou R, Wang Q, Zhang T, et al. Immunogenicity and effectiveness of an mRNA therapeutic vaccine for HPV-related malignancies. Life Science Alliance. 2024;7(6):e202302448. doi:10.26508/lsa.202302448
BibTeX
@article{Wang2024,
author = {Wang, Jing and Ma, Ling and Chen, Yunfeng and Zhou, Rui and Wang, Qixin and Zhang, Tingting and Yi, Dongrong and Liu, Qian and Zhang, Yongxin and Zhang, Weiguo and Dong, Yijie and Cen, Shan},
title = {Immunogenicity and effectiveness of an mRNA therapeutic vaccine for HPV-related malignancies},
journal = {Life Science Alliance},
year = {2024},
volume = {7},
number = {6},
pages = {e202302448},
doi = {10.26508/lsa.202302448}
}
EUVIMED